{"title":"信息图:使用雷尼珠单抗治疗新生血管性老年黄斑变性的端口给药系统:LADDER试验","authors":"Ishani Barai, Sobha Sivaprasad, Christin Henein","doi":"10.1038/s41433-024-03337-1","DOIUrl":null,"url":null,"abstract":"<p><b>Reference to original article:</b></p><p>Campochiaro, P. A., Marcus, D. M., Awh, C.C. et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology, 126(8), 1141–1154.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Infographic: The port delivery system with ranibizumab for neovascular age-related macular degeneration: LADDER trial\",\"authors\":\"Ishani Barai, Sobha Sivaprasad, Christin Henein\",\"doi\":\"10.1038/s41433-024-03337-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><b>Reference to original article:</b></p><p>Campochiaro, P. A., Marcus, D. M., Awh, C.C. et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology, 126(8), 1141–1154.</p>\",\"PeriodicalId\":12125,\"journal\":{\"name\":\"Eye\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eye\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41433-024-03337-1\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41433-024-03337-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
原文参考文献:Campochiaro, P. A., Marcus, D. M., Awh, C.C. et al.使用雷尼珠单抗治疗新生血管性年龄相关性黄斑变性的端口给药系统:随机2期阶梯临床试验结果。眼科学》,126(8),1141-1154。
Infographic: The port delivery system with ranibizumab for neovascular age-related macular degeneration: LADDER trial
Reference to original article:
Campochiaro, P. A., Marcus, D. M., Awh, C.C. et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology, 126(8), 1141–1154.
期刊介绍:
Eye seeks to provide the international practising ophthalmologist with high quality articles, of academic rigour, on the latest global clinical and laboratory based research. Its core aim is to advance the science and practice of ophthalmology with the latest clinical- and scientific-based research. Whilst principally aimed at the practising clinician, the journal contains material of interest to a wider readership including optometrists, orthoptists, other health care professionals and research workers in all aspects of the field of visual science worldwide. Eye is the official journal of The Royal College of Ophthalmologists.
Eye encourages the submission of original articles covering all aspects of ophthalmology including: external eye disease; oculo-plastic surgery; orbital and lacrimal disease; ocular surface and corneal disorders; paediatric ophthalmology and strabismus; glaucoma; medical and surgical retina; neuro-ophthalmology; cataract and refractive surgery; ocular oncology; ophthalmic pathology; ophthalmic genetics.